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Abstract
Transactive response DNA-binding protein 43 kDa (TDP-43) was identified as a major disease-associated component in 
the brain of patients with amyotrophic lateral sclerosis (ALS), as well as the largest subset of patients with frontotemporal 
lobar degeneration with ubiquitinated inclusions (FTLD-U), which characteristically exhibits cytoplasmic inclusions that 
are positive for ubiquitin but negative for tau and α-synuclein. TDP-43 pathology occurs in distinct brain regions, involves 
disparate brain networks, and features accumulation of misfolded proteins in various cell types and in different neuroanatomi-
cal regions. The clinical phenotypes of ALS and FTLD-TDP (FTLD with abnormal intracellular accumulations of TDP-43) 
correlate with characteristic distribution patterns of the underlying pathology across specific brain regions with disease 
progression. Recent studies support the idea that pathological protein spreads from neuron to neuron via axonal transport 
in a hierarchical manner. However, little is known to date about the basis of the selective cellular and regional vulnerability, 
although the information would have important implications for the development of targeted and personalized therapies. 
Here, we aim to summarize recent advances in the neuropathology, genetics and animal models of TDP-43 proteinopathy, 
and their relationship to clinical phenotypes for the underlying selective neuronal and regional susceptibilities. Finally, we 
attempt to integrate these findings into the emerging picture of TDP-43 proteinopathy, and to highlight key issues for future 
therapy and research.
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Introduction
The pathology of proteinopathies appears in distinct brain 
regions, involves disparate brain networks, and features 
accumulation of misfolded proteins in various cell types 
and in different neuroanatomical regions. The clinical phe-
notypes of these diseases correlate with the characteristic 
distribution patterns of the underlying pathology across 
specific brain regions with disease progression. Individuals 
may exhibit rapid or slow neurodegeneration even within 
the same syndrome. However, little is known to date about 
the reasons for this, although an understanding of the basis 
of the selective cellular and regional vulnerability would 
be helpful for the development of targeted and personal-
ized therapies. Notably, there is growing evidence that these 
proteinopathies are modulated by genetic risk factors, dif-
ferences in the conformation of pathological proteins, and 
various environmental factors. These factors may play a role 
in differential cellular susceptibility or resilience, and hence 
result in phenotypic diversity.
Transactive response DNA-binding protein 43 kDa (TDP-
43) was identified as a major disease-associated component 
in the brain of patients with amyotrophic lateral sclerosis 
(ALS) and the largest subset of patients with frontotemporal 
lobar degeneration with ubiquitinated inclusions (FTLD-U) 
[6, 116]. FTLD-U has characteristic cytoplasmic inclu-
sions, which are positive for ubiquitin but negative for tau 
and α-synuclein. The terminology FTLD-TDP has been 
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recommended for the neuropathological subtype of FTLD 
characterized by abnormal intracellular accumulations of 
TDP-43 [44, 48, 99, 102, 114, 143].
In this review, we summarize recent advances in the 
neuropathology, genetics and animal models of TDP-43 
proteinopathy, and discuss their relationship to clinical 
phenotypes, their place in the emerging picture of TDP-43 
proteinopathy, and their relevance to the development of 
therapeutic interventions.
Cellular and molecular basis of TDP‑43 
aggregation
Structure, function and localization of TDP‑43
TDP-43 was originally discovered in a screen for protein fac-
tors that bind the long terminal repeat transactive response 
element of HIV-1 [119]. Several studies have revealed that 
TDP-43 can bind both DNA and RNA [31, 32, 94]. There is 
evidence that TDP-43 plays a role in transcription, alterna-
tive splicing and messenger RNA (mRNA) stability, and is 
involved in various cellular processes, including apoptosis, 
cell division and axonal transport [31, 94]. The capacity of 
TDP-43 to interact with RNA, including mRNA and pre-
mRNA, is considered to underlie the role in exon splicing. 
TDP-43 is a heterogeneous nuclear ribonucleoprotein with 
two RNA recognition motifs (RRM-1 and 2) in the mid-
dle portion [93] and a glycine-rich domain and glutamine/
asparagine (Q/N)-rich domain in the C-terminal region. 
Most mutations in TDP-43 are clustered in the C-terminal 
region [87], which is essential for some of the most well-
characterized functions of TDP-43, including the protein’s 
role as a gene splicing factor [119] (Fig. 1).
TDP-43 shuttles between the nucleus and cytoplasm 
under physiological conditions, and a nuclear localiza-
tion signal enables the active import of the protein into the 
nucleus [93, 159]. The majority of TDP-43 resides in the 
nucleus, but up to 30% of TDP-43 resides in the cytoplasm 
[17]. Export is mainly driven by passive diffusion, and TDP-
43 is predominantly localized in the nucleus in the healthy 
state [93]. Under pathophysiological conditions, TDP-43 is 
cleared from the nucleus and accumulates in the cytoplasm 
[6, 68, 114]. The translocation into the cytoplasm has been 
considered to be a consequence of impaired nuclear trans-
port and solubility of TDP-43 [159]. This is consistent with 
findings that seeded aggregation of TDP-43 in cytoplasm 
may induce the mislocalization of TDP-43 by impairing 
nuclear transport [17], and that proteins playing a role in 
nucleocytoplasmic transport are present in pathological 
TDP-43 aggregates [37].
The neurotoxicity of pathological TDP-43 protein has not 
been fully clarified. Although the redistribution of TDP-43 
from the nucleus to the cytoplasm is generally considered 
to cause loss of TDP-43 nuclear function [32], some studies 
have found that nuclear depletion is not necessary for neu-
ronal toxicity induced by ALS-associated mutant TDP-43 
[10, 13], and that cytoplasmic mutant TDP-43 has an impor-
tant role in neurodegeneration [17]. More recent animal 
model studies support the hypothesis that TDP-43 progres-
sion is induced by a gain of toxic function in the cytoplasm, 
in addition to the loss of nuclear function, and that both are 
involved in the progression of TDP-43 proteinopathy [50, 
51, 57, 138]. Understanding in detail how TDP-43 leads to 
neurodegeneration will help direct future therapy.
TDP aggregates and their molecular alterations
Biochemical, immunochemical and protein-chemical analy-
ses of materials isolated from the brains of patients with 
TDP-43 proteinopathies have uncovered the characteristic 
features of pathological TDP-43. Immunoelectron-micro-
scopic studies demonstrated that the protein accumulates as 
abnormal fibrils or filaments with cellular organelles, irregu-
larly shaped structures and lipofuscins. The fibrils appear to 
be amyloid-like, even though they are intracellular proteins, 
Fig. 1  Schematic diagram of TDP-43 functional regions involved in 
the pathogenesis and progression of TDP proteinopathy. TDP-43 in 
human brain is a heterogenous ribonucleoprotein with two RNA rec-
ognition motifs (RRM-1 and 2) in the middle portion and with a gly-
cine-rich domain and Q/N-rich domain in the C-terminal region. Pro-
tein in abnormal conformations is accumulated in brains of patients 
in the form of amyloid-like fibril structures. The blue arrow indicates 
the protease-resistant fibril core. Mapping of three selected antibodies 
to the TDP-43 protein is shown. Antibodies in italics are widely used 
in TDP-43 immunohistochemical studies [62]. NLS nuclear locali-
zation signal, RRM RNA-recognition motif, Gly-rich glycine-rich 
domain
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whereas the classical histopathological “amyloid” exists as 
extracellular proteinaceous deposits exhibiting beta sheet 
structure [6, 68, 116]. More extensive studies demonstrated 
that the protein is poorly sarkosyl-soluble, hyperphosphoryl-
ated, ubiquitinated, and abnormally cleaved into small frag-
ments (C-terminal fragments) [6, 68, 86, 116]. These data 
indicate that functional consequences might ensue from the 
distinctive differences between normal and abnormal TDP-
43 (Fig. 2a). It has been suggested that aggregation-prone 
N-terminal fragments produced by proteolytic cleavage may 
cause TDP-43 pathologies, but TDP-43 cleavage peptides 
generated by enzymes such as caspase or calpain have not 
been detected by nano-flow liquid chromatography–ion trap 
mass spectrometry [86]. Furthermore, aggregation of full-
length TDP-43 precedes generation of TDP-43 C-terminal 
fragments in the seeded cellular model of TDP-43, suggest-
ing that production of C-terminal or N-terminal fragments 
is not essential for the formation of intracellular TDP-43 
aggregates [86].
As in other neurodegenerative diseases, hyperphospho-
rylation seems to occur in the aggregated TDP-43 proteins. 
Many phosphorylation sites, including serine, threonine, or 
tyrosine residues, have been reported within TDP-43 in cel-
lular experiments, and these residues may have some func-
tional role in TDP-43. However, intensive immunochemi-
cal studies using more than 20 phosphorylation-site-specific 
Fig. 2  Postulated molecular mechanisms of accumulation and prop-
agation of pTDP-43 in human brain. a Normal physiological status 
and pathophysiological status of TDP-43 in human brain. As shown 
on the left, TDP-43 primarily resides in the nucleus and is trafficked 
between the nucleus and cytoplasm in the cells under normal physi-
ological conditions. TDP-43 has roles in regulating gene expression 
at the transcriptional level, regulating gene splicing, and stabiliz-
ing mRNA. Under pathophysiological conditions in patients with 
pTDP pathology (right), TDP-43 is cleared from the nucleus and 
accumulates in the cytoplasm. Pathological TDP-43 is fragmented 
into C-terminal fragments, which are hyperphosphorylated, ubiquit-
inated and less soluble, and might represent immature products avail-
able for aggregation. P phosphorylated, TDP-43 TAR DNA-binding 
protein 43, U ubiquitinated. b TDP-43 proteinopathy can involve 
several strains of seeds. Each pTDP-43 strain accumulates in differ-
ent cell types and regions of the central nervous system. The strains 
move from one region to another, maintaining their original form. All 
of these phenomena may contribute to selective local vulnerability. 
The expression levels of isoforms of the cognate proteins may differ 
among cells and compartments, thereby promoting or restricting the 
spread of the seeds and defining the strain of seed that is propagated
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antibodies for the human TDP-43 sequence revealed that 
several of the antibodies (pS379, pS403/404, pS409, pS410 
and pS409/410) stained the pathological TDP-43 inclusions. 
These antibodies specifically recognize hyperphosphoryl-
ated full-length and cleaved forms of abnormal TDP-43, and 
thus are frequently used for immunostaining and immuno-
blotting studies [62, 68]. The phosphorylation and frag-
mentation were recapitulated in a cellular model of seeded 
aggregation of TDP-43 [117] (Fig. 2a). In addition, recom-
binant full-length human TDP-43 forms structurally stable, 
spherical oligomers that are neurotoxic in vitro and in vivo 
[50]. In fact, cellular aggregate formation or accumulation 
of TDP-43 C-terminal fragments is not primarily responsi-
ble for the development of the observed disease phenotype 
in mutant or wild-type TDP-43 mice [43]. These findings 
also suggest that full-length TDP-43, not the cleavage frag-
ments, participates at an early stage in TDP-43 pathology 
and also fragmentation might occur after the accumulation 
of TDP-43 [86].
Notably, patients with PGRN gene (GRN) mutations have 
high frequency of neuronal intranuclear inclusions (NIIs) 
containing TDP-43. The formation mechanism of NIIs is still 
unknown, but one possibility is that the production of NIIs 
might be associated with the deficiency of PGRN, which is 
involved in the regulation of lysosomal function since this 
would lead to the increased lysosomal gene expression and 
protein levels [144, 145] (Fig. 2a).
Physiological microenvironments associated 
with neuronal toxicity
Previous research on physiological microenvironments asso-
ciated with neurodegeneration in TDP-43 proteinopathy has 
focused on stress granules (SGs). These are membrane-less 
discrete cytoplasmic structures, containing mRNA and asso-
ciated proteins that form in cells as a protective response to 
stress [30]. SGs have long been thought that they contribute 
to some degenerative diseases, including ALS, FTD, myo-
pathy, and possibly AD and other tauopathies [12, 29, 150]. 
Many prior studies suggest that TDP-43 and other diseases 
associated with RNA-binding proteins colocalize with SGs, 
and SGs might regulate the translational stress response 
[151]. However, it is still unclear whether TDP pathology 
arises from SG pathology since colocalization of TDP-43 
and SG proteins is hardly observed in human brains [160]. 
Recent papers demonstrate that cytoplasmic inclusions 
containing aggregated pTDP-43 can develop through three 
pathways: direct aggregation or phase-separated intermedi-
ates involving ejection from SGs or seeding with exogenous 
fibrils [58, 105]. These studies suggest that pathological 
TDP-43 granules are distinct from SGs, although in some 
cases SG appears to serve as an intermediate. They also indi-
cate that most of the nuclear pore proteins do not colocalize 
with TDP-43 aggregates, implying that the aggregation 
occurs through an independent process [58, 105].
TDP‑43 expression in non‑neuronal cells
In addition to neurons, TDP-43 is abundantly expressed in 
glia, as well as many other cell types. Oligodendrocytes with 
accumulations of pTDP-43 frequently appear in FTLD/ALS 
brains [5, 26], and TDP-43-positive inclusions in astrocytes 
have been recognized in Alexander’s disease [152]. Basi-
cally, microglia play a role in mediating neurotoxicity and 
neuroprotection, and maintaining homeostasis, including 
control of the formation of synapses, refining neuronal cir-
cuits, eliminating redundant synapses, and healing responses 
to injury [139].
Recent studies of mice with TDP-43 pathology induced 
with TDP-43 from patients with TDP-43 proteinopathy 
established that white matter oligodendrocytes and astro-
cytes are capable of developing phosphorylated TDP-43 
aggregates [122], and abundant reactive microglia selec-
tively cleared neuronal human TDP-43 [74]. Studies in ani-
mal models of other proteinopathies, such as α-synuclein, 
have also described neurodegeneration with inflammation, 
and activated microglia [136]. These findings suggest that 
inclusions or degenerating neurons with aggregates may be 
cleared by microglial phagocytosis, which may account for 
the neuroprotective action of microglia [136, 139]. Modula-
tion of microglia-mediated function during the progression 
of TDP-43 pathology may have potential as a new thera-
peutic strategy.
Phenotypic diversity in TDP‑43 
proteinopathy
Clinical phenotypic diversity in TDP‑43 
proteinopathy
Many neurodegenerative diseases, such as Alzheimer’s 
disease (AD), Parkinson’s disease (PD), and amyotrophic 
lateral sclerosis (ALS), are classified according to their clini-
cal symptoms and neuropathological features. Indeed, major 
clinical symptoms correspond well to the anatomical brain 
regions showing neuronal loss with reactive gliosis. These 
pathological changes are associated with the accumula-
tion of abnormal proteins with conformational changes and 
modifications, which occur intracellularly in neurons or glial 
cells, or extracellularly [89].
ALS and FTLD-TDP are sporadic and familial neuro-
degenerative diseases characterized neuropathologically by 
cellular aggregates of TDP-43. The differences in TDP-43 
pathology are associated with differences in clinical mani-
festations, and ALS and FTLD are generally diagnosed on 
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the basis of clinical symptoms. However, some patients may 
show symptoms common to both diseases. For example, 
clinical overlap between ALS and behavioral variant fron-
totemporal dementia (bvFTD) has been recognized, with up 
to 50% of ALS patients showing some executive function 
deficits [98, 127]. Also, up to 15% of bvFTD patients show 
motor neuron dysfunction [34, 127].
There are three major clinical phenotypes of frontotem-
poral lobar degeneration (FTD): bvFTD, semantic variant 
primary progressive aphasia (svPPA) and nonfluent/agram-
matic primary progressive aphasia (naPPA) [36, 44, 48]. 
Each clinical syndrome among these diseases is associated 
with topographically distinct cerebral involvement, based 
on pathological protein deposits. bvFTD is associated with 
symmetrical (though sometimes right-sided) frontotemporal 
dysfunction, svPPA with left anterior temporal deficits and 
naPPA with left frontotemporal dysfunction (Fig. 3).
Loss of empathy, apathy, and selfishness are more fre-
quent features of bvFTD, but may be found commonly in all 
subtypes [18]. These symptoms are associated with atrophy 
and dysfunction of the right anterior cingulate cortex and 
superior frontal gyrus, while disinhibition is associated with 
the right subgenual cingulate cortex and orbitofrontal cortex 
[121, 163], overeating with an orbitofrontal striatal circuit 
[161], and executive dysfunction with the dorsolateral and 
prefrontal cortex [73]. Fluent speech, progressive impair-
ment of single-word comprehension, preserved articulatory 
abilities, and dysfunction of semantic memory are features 
of svPPA [63]. Patients with naPPA show apraxia of speech 
or expressive agrammatism: single-word comprehension and 
object knowledge are relatively preserved, and behavioral 
symptoms are less common in comparison with their high 
frequency in svPPA. Cognitive decline, dementia, and altera-
tions in high-order brain functions are associated with the 
involvement of the limbic region, including the entorhinal 
cortex and hippocampus, and neocortical areas. Most svPPA 
can be classified into TDP proteinopathy, whereas bvFTD 
and naPPA are correlated with FTLD-tau [137].
TDP‑43 pathology in aged brains and other 
neurodegenerative diseases
In FTLD-TDP and ALS, neuronal loss, reactive gliosis, 
microglial activation and superficial laminar spongiosis 
are seen in the neocortex and hippocampus [48]. TDP-43 
pathology is present throughout the CNS with relative pres-
ervation of the occipital cortex and cerebellum [61]. Sub-
cortical areas, including the nucleus accumbens, basolat-
eral amygdala and caudate/putamen, are also progressively 
affected [61]. In movement disorders such as ALS, the basal 
ganglia, thalamus, brainstem nuclei, cerebellar cortex and 
nuclei, motor cortical areas and lower motor neurons of the 
spinal cord are involved. These findings suggest that selected 
neuronal populations may be particularly vulnerable to TDP-
43 aggregates. TDP-43 immunoreactive structures include 
neuronal cytoplasmic inclusions (NCIs), neuronal pre-
inclusions, dystrophic neurites (DNs), neuronal intranuclear 
inclusions (NIIs), and glial cytoplasmic inclusions (GCIs).
The deposited protein is hyperphosphorylated, ubiquit-
inated and abnormally cleaved to generate C-terminal frag-
ments [6, 68, 116]. The phosphorylation sites of abnormal 
TDP-43 are located at Ser379, Ser403, Ser404, Ser409 and 
Ser410. TDP-43 inclusions are thioflavin-S positive [22], 
suggesting that TDP-43 is accumulated as amyloid-like 
fibrils.
TDP-43-positive NCIs are frequently found in the fron-
totemporal neocortex and dentate granule cells of the hip-
pocampus in ALS, FTLD and FTLD–MND [76, 118, 157]. 
They are also positive for ubiquitin and p62, but negative 
for tau, α-synuclein, amyloid beta and FUS [6, 36, 44, 116, 
118]. Skein-like and spherical or round inclusions are pre-
sent in motor neurons in ALS. These inclusions are detected 
in 100% of TDP proteinopathy brains. Diffuse or granular 
or dash-like cytoplasmic inclusions, which are dispersed 
throughout the neuronal somatodendritic domain, are found 
in motor neurons of cranial nerve nuclei or spinal cord of 
ALS and FTLD-TDP [44, 60]. These inclusions are consid-
ered to be in a transitional state and are referred to as “pre-
inclusions”, since they are negative for ubiquitin and p62 
[5]. As for DNs, two types of DNs, short DNs and elongated 
DNs, have been recognized [36, 71]. Both types of DNs are 
typically most numerous in layer II of the frontal and tempo-
ral cortices, although the elongated DNs are generally more 
widely dispersed throughout the entire cortex in comparison 
Fig. 3  Specific topographic patterns of atrophy in FTLD-TDP. bvFTD 
predominantly shows frontal lobe atrophy, svPPA shows left anterior 
temporal tip atrophy, and naPPA shows left frontotemporal atrophy. 
Each clinical syndrome is associated with distinct cerebral involve-
ment behavioral variant FTD: bvFTD, semantic variant PPA: svPPA, 
nonfluent/agrammatic PPA: naPPA
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with the short DNs [71]. NIIs show a lentiform or “cat’s eye” 
appearance and are present in small neurons in multiple neu-
roanatomical sites. They appear frequently in familial cases 
[60]. GCIs with coiled body-like or globular morphologies 
are frequently found in the cerebral white matter and the 
spinal cord in ALS and FTLD–MND [27, 71, 115]. GCIs 
are positive for TDP-43 and p62, but are mostly negative for 
ubiquitin [9, 60]. Most GCIs are considered to be of oligo-
dendrocytic origin on the basis of double immuno-labeling 
for pTDP-43 and a complement protein, C4d [7] (Fig. 4).
TDP-43 pathology is typically classified into four sub-
types (types A–D) in FTLD-TDP, based on the predominant 
type of TDP-43-positive structures and their distribution 
[101]. Type A is characterized by numerous short DNs and 
crescentic or oval NCIs; type B shows NCIs throughout all 
cortical layers with few DNs; type C presents a predomi-
nance of elongated DNs in upper cortical layers with few 
NCIs; and type D is characterized by numerous short DNs 
and frequent lentiform NIIs (Figs. 2b, 5a). Recently, a new 
type, type E, was identified, in which granulofilamentous 
neuronal inclusions, abundant grains, and oligodendroglial 
inclusions were prominent [95].
TDP pathology should be evaluated from multiple 
points of view. Neuropathological comorbidity has recently 
attracted attention. TDP-43 pathology frequently appears 
in other neurodegenerative diseases, including AD, argy-
rophilic grain disease (AGD), dementia with Lewy bod-
ies (DLB), chronic traumatic encephalopathy (CTE), hip-
pocampal sclerosis (HS), and Guam ALS [8, 61, 67, 90, 
109, 113, 162]. Concomitant TDP-43 pathology has a 
significant impact on the clinical features of AD [82, 83]. 
TDP-43 pathology in AD has been classified into six stages, 
supported by correlations with neuroimaging and clinical 
features [82, 83]. It begins with the amygdala (stage I), then 
spreads into the subiculum and entorhinal cortex (stage II), 
and involves the dentate gyrus and occipitotemporal cortex 
(stage III). Next, the insular, ventral striatum, basal forebrain 
and inferior temporal cortex are affected (stage IV). Then it 
appears in the substantia nigra, inferior olive nucleus, and 
midbrain tectum (stage V), and finally in the basal ganglia 
and middle frontal cortex (stage VI) [82, 83]. Progression 
is associated with impaired cognition, memory loss, and 
medial temporal atrophy in AD [83]. Concomitant TDP-43 
pathology was also found in 53–60% of DLB cases, 60% of 
AGD cases (Fig. 3e) and 100% of Huntington’s disease cases 
[8, 57, 130]. TDP pathology was seen in 89.9% of patients 
with HS compared with 9.7% of patients without HS [113]. 
TDP-positive inclusions and neurites were also found in 
36–85% of CTE cases, ranging from early to late stage [109].
TDP-43 pathology is present in a high proportion of cog-
nitively normal elderly persons [11]. In cases of primary 
age-related tauopathy (PART), which is characterized by the 
presence of neurofibrillary tangles (NFTs) in the limbic and 
brain stem region and absent-minimal β-amyloid deposition 
[41], 26.7% have TDP-43 pathology and the presence of 
TDP-43 was associated with significantly greater amygdala, 
hippocampal, and anterior temporal atrophy [80].
As we described above, TDP-43 pathology frequently 
occurs in AD and DLB cases. In 20–30% of these cases, the 
morphological pattern of cortical TDP-43 immunoreactiv-
ity and the band pattern of C-terminal fragments of insolu-
ble TDP-43 on immunoblots are similar to those of type A 
FTLD-TDP, which is seen in cases with GRN mutation [8].
Another study classified TDP-43 pathology in non-FTLD 
brains into two subtypes, TDP type-α and TDP type-β. The 
former shows typical TDP-43 immunoreactive inclusions, 
while the latter is characterized by the presence of TDP-43 
immunoreactivity adjacent to/associated with NFTs in the 
same neuron [81]. The age at death of type-α was older than 
that of type-β (median 89 years vs. 87 years). Hippocampal 
sclerosis was present in 60% of type-α patients and 15% of 
type-β patients. A pattern of widespread TDP-43 deposition 
commonly extended into the temporal, frontal and brain-
stem regions in type-α, whereas TDP-43 deposition was 
predominantly located in limbic regions, including amyg-
dala, entorhinal cortex and subiculum of the hippocampus 
in type-β [81]. The frequency of TMEM106B protective 
(GG) and risk (CC) haplotypes (SNP rs3173615 encoding 
p.T185S) is high in type-α compared to type-β in non-FTLD-
TDP cases [81] (Fig. 6).
Recently, the new term limbic-predominant age-related 
TDP-43 encephalopathy (LATE) was proposed to describe 
the presence of TDP-positive lesions in AD, as well as in 
older adults [112]. LATE neuropathological change (LATE-
NC) is defined by a stereotypical TDP-43 proteinopathy in 
older adults, with or without coexisting hippocampal sclero-
sis pathology, and is distinguished from FTLD-TDP. LATE-
NC is also a common TDP-43 proteinopathy associated 
with an amnestic dementia syndrome similar to AD. LATE 
includes already characterized phenotypes, but involves 
no new TDP-43 pathologic subtype, no link between TDP 
pathology with new cognitive symptoms, and no character-
istic biochemistry [79]. Although the term aims to encourage 
future research, as well as development of neuroimaging 
and molecular biomarkers, the concept may be confusing in 
relation to AD and should be considered further.
Genetic predisposition leading 
to differential vulnerability
The pathological classification of TDP-43 proteinopathy 
is supported by clinical and genetic correlations. svPPA is 
associated with type C, and FTLD-MND or clinical signs of 
MND with type B, and naPPA with type A, although bvFTD 
is not as strongly correlated with any special pathological 
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Fig. 4  Pathological features of TDP-43-positive structures. Macro-
scopic photograph of an FTLD-TDP patient’s brain. The left hemi-
sphere shows severe atrophy in the frontal cortex and mild atrophy in 
the temporal tip (a). TDP-43-positive structures detected in patients 
with TDP proteinopathy. The dentate gyrus of the hippocampus 
shows neuronal cytoplasmic inclusions (NCI) with no nuclear stain-
ing (b). Rounded NCI in the entorhinal cortex (c), skein-like inclu-
sions in the lower motor neurons (d), and inclusions with granular 
appearance in the amygdala (e) can be seen. There are dystrophic 
neurites (DNs) in the temporal cortex (f). Neuronal intranuclear 
inclusions with a “cat’s eye” shape are present in the entorhinal cor-
tex (g) and glial cytoplasmic inclusions are seen in temporal white 
matter (h). b–h Stained with phosphorylated TDP-43-specific anti-
body (pS409/410). Scale bars: a 1.5 cm; b, d, f 20 μm; c, e, g 10 μm
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type [21, 78, 85, 100]. Most cases of ALS/FTLD are spo-
radic but ~ 5% is familial. Regarding the genetics, clinical 
clusters of FTD and ALS have been reported to be asso-
ciated with several genes, including granulin precursor 
(GRN) [15, 42], valosin-containing protein (VCP) [153], 
TAR DNA-binding protein (TARDBP) [85, 91], chromosome 
9 open reading frame 72 gene (C9orf72) [45, 100, 124], 
sequestosome 1 (SQSTM1) [148], ubiquilin 2 (UBQLN2) 
[46], TANK-binding kinase 1(TBK1) [56], T cell-restricted 
intracellular antigen-1 gene (TIA1) [103], cyclin F (CCNF) 
[158], coiled-coil-helix-coiled-coil-helix domain-contain-
ing protein 10 (CHCHD10) [16] and optineurin (OPTN) 
[35]. Superoxide dismutase 1(SOD1) has also been linked 
with ALS [128]. C9orf72 repeat expansion is the most fre-
quent genetic factor in sporadic and familial cases [2, 33, 
66], but 40% of familial cases have no established genetic 
cause, and unknown genes may be involved [2, 66]. Cases 
with a C9orf72 expansion repeat mutation have additional 
p62-positive and TDP-43-negative NCIs, which are com-
posed of dipeptide repeat proteins (translated from the 
C9orf72 expansion repeats) [100]. Psychotic symptoms, 
such as delusions and hallucinations, are likely to present 
in C9orf72 repeat expansion carriers [47, 138], although 
they are generally rare in FTD [97]. Also, family members 
of patients carrying C9orf72 repeat expansion might have 
high incidences of psychiatric illness [47]. GRN is mostly 
associated with type A, and C9orf72 with type B, or less 
commonly with type A [100, 101]. Associated genes are still 
unknown in types C and E [95]. Type D has been reported 
to be highly associated with inclusion body myopathy with 
early-onset Paget disease of bone and frontotemporal demen-
tia (IBMPFD) caused by VCP mutations. Missense muta-
tions in VCP affect various cellular processes, including 
ubiquitin-dependent protein quality control, cell division, 
and nuclear envelope formation [110]. As a result, the con-
solidation of aggregate-prone proteins into inclusion bodies 
Fig. 5  Pathological and biochemical classification of TDP pro-
teinopathy. a FTLD-TDP subtypes A to C. Type A is characterized 
by numerous neuronal cytoplasmic inclusions (NCIs) and short dys-
trophic neurites (DNs). This type frequently has neuronal intranu-
clear inclusions (NII) in the affected regions; type B shows numerous 
NCIs; type C has long and tortuous DNs. b Immunoblots of insoluble 
TDP-43 from patients with TDP proteinopathy, probed using anti-
phosphorylated TDP-43 antibody (pS409/410). The band patterns of 
TDP-43 C-terminal fragments from the three TDP-43 types are differ-
ent (shown schematically on the left). Type B has three major bands 
at 23, 24 and 26 kDa and two minor bands at 18 and 19 kDa (lane 2). 
Type C has two major bands at 23 and 24 kDa and two minor bands 
at 18 and 19  kDa (lane 3). Type C has an intense band at 23  kDa, 
whereas type B has a strong 24 kDa band. The band pattern of type 
A seems intermediate between types B and C (lane 1). Molecu-
lar weight markers of migrated protein standards are shown in kDa. 
Scale bar: 20 μm
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via multivesicular body formation is induced and causes the 
pathogenic features [149].
Various related genes, apolipoprotein E (APOE), granu-
lin (GRN), transmembrane protein 106B (TMEM106B), 
ATP-binding cassette sub-family member 9 (ABCC9) and 
potassium channel subfamily M regulatory beta subunit 2 
(KCNMB2), have been reported to be risk alleles associated 
with pathological manifestations in FTLD-TDP and LATE 
[112].
Progression pattern of TDP‑43 pathology 
in human brains
Clinical phenotypes are associated with characteristic dis-
tribution patterns of the pathology in the course of disease 
progression. The progression pattern of TDP-43 pathology 
has been identified [26, 27]. In bvFTD, pTDP-43 pathology 
progresses in four distinct topographic stages [26]. Stage I 
involves the orbital gyri, gyrus rectus, and amygdala, and 
stage II progresses to the middle frontal and anterior cingu-
late gyrus as well as anteromedial temporal lobe areas, the 
superior and medial temporal gyri, striatum, red nucleus, 
thalamus, and precerebellar nuclei. Stage III shows involve-
ment of the motor cortex, bulbar somatomotor neurons, and 
the spinal cord anterior horn, whereas finally, stage IV shows 
the highest burden of pathology in the visual cortex [26]. 
bvFTD is associated with all subtypes of TDP pathology. In 
the case of svPPA with type C, the progression pattern of 
TDP-43 pathology is not yet established.
The progression pattern of pTDP-43 in ALS patients has 
also been characterized [24, 27]. ALS with TDP deposition 
begins in the upper motor neurons in the cortex, lower motor 
neurons in the spinal cord and lower brainstem (stage I). 
Stage II progresses gradually to posterior frontal and ante-
rior parietal regions, brainstem reticular formation, and red 
nucleus. Stage III involved the anterior frontal and basal 
forebrain, striatum, thalamus (mediodorsal/lateral thalamus), 
and substantia nigra. Finally, patients show involvement of 
the anterior temporal lobe including hippocampus (stage IV) 
[24, 27] (Fig. 7).
Methods for assessing clinical phenotypic 
diversity
Several methods have been developed with the aim of 
identifying the differences between TDP-43 and other pro-
teinopathies. Many researchers have investigated TDP-43 
in cerebrospinal fluid (CSF) since it is considered to reflect 
Fig. 6  Clinical, pathological, and genetic spectra of TDP proteinopa-
thy. ALS amyotrophic lateral sclerosis, bvFTD behavioral variant 
frontotemporal dementia, MND motor neuron disease, naPPA non-
fluent/agrammatic PPA, svPPA semantic variant PPA, GRN granulin, 
VCP valosin-containing protein
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the TDP pathology in human brain. However, the results are 
conflicting. One report found that ALS and FTLD patients 
had higher TDP-43 levels in CSF, compared to control 
patients [141], but another report indicated that TDP-43 CSF 
levels were higher in ALS, in comparison with FTLD [84]. 
In the latter paper, there was a difference in C9orf72 muta-
tion between ALS and FTLD patients, but no difference was 
detected between carriers and non-carriers. Furthermore, a 
non-significant trend of lower pTDP-43 levels in ventricu-
lar CSF was reported in FTLD-TDP compared to controls 
[92]. These results suggest that TDP-43 CSF level does not 
adequately reflect TDP-43 pathology, and may not be a use-
ful biomarker [140]. Further, TDP-43 analysis in blood is not 
yet available for the diagnosis of TDP-43 pathology, due to 
the lack of sufficiently sensitive quantification methods [53, 
54]. However, more advanced methods should be developed 
in the near future.
Several neuroimaging studies of FTLD-TDP and ALS 
have been reported. Volumetric structural MRI scans, cor-
tical thickness analyses, diffusor tensor imaging, and to a 
Fig. 7  Progression of TDP pathology in bvFTD and ALS The upper 
figure shows TDP-43 pathology progression in behavioral variant-
frontotemporal dementia (bvFTD) of Types A and B, possibly prop-
agating along axonal pathways. Stage 1: pTDP-43 pathology begins 
with neurons and oligodendrocytes of the basal and anterior portions 
of the prefrontal neocortex and amygdala. Stage 2: the pathology 
appears caudal to the frontal lobe, including the middle frontal gyrus, 
insular cortex, and anterior cingulate gyrus, and also in anteromedial 
areas, including the hippocampus (H), the caudate nucleus and puta-
men (C/P), and the mediodorsal nucleus (MD) of the thalamus (T), 
red nucleus (R), precerebellar nuclei (PC), and dorsomedial medul-
lary regions. Stage 3: TDP pathology is increased compared to the 
first two stages and has spread further into the cortical, brainstem, 
and spinal motor regions. Stage 4 cases with the highest burden of 
pathology, showing pTDP-43 deposits in the occipital neocortex 
(visual cortex, Brodmann 17, 18) Amyotrophic lateral sclerosis 
(ALS) with TDP-43 pathology is shown in the lower figures. Stage 
1: pTDP-43 deposition begins (stage 1) in the agranular motor cor-
tex, or lower motor neurons in the spinal cord and lower brainstem. 
Stage 2: increasing burden of TDP-43 pathology, with progression to 
the posterior frontal and anterior parietal regions, brainstem reticu-
lar formation (RF), PC and R. Stage 3: TDP pathology involves the 
anterior frontal and basal forebrain, the C/P, MD and lateral thalamus 
(LT), and substantia nigra (SN), Stage 4: TDP pathology has spread 
into the anterior temporal lobe, including the H. cornu ammonis sub-
regions 1 and 2 of the hippocampus (CA1–2), hypoglossal nucleus 
(XII), and inferior olivary complex (IOC) Figures are adapted from 
Brettschneider et al. with permission from the copyright holder [26, 
27]
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lesser extent functional techniques, including functional 
MRI and FDG-PET have been utilized to aid diagnosis in 
clinical practice [20, 33]. Generally, patients with FTLD 
classically show frontal and temporal atrophy, involving 
the orbitofrontal/dorsolateral prefrontal cortices and the 
temporal poles, and hypometabolism in these regions is 
often asymmetrical. As mentioned above, there are charac-
teristic patterns of atrophy in the three clinical phenotypes 
of FTLD. MRI or positron emission tomography (PET) 
findings have revealed frontal and/or anterior temporal 
atrophy or hypometabolism in bvFTD [123], left poste-
rior frontoinsular atrophy, hypoperfusion or glucose hypo-
metabolism in naPPA, and predominant anterior tempo-
ral lobe atrophy or hypoperfusion or hypometabolism in 
svPPA [64, 129]. In the diagnosis of ALS, imaging is used 
only for exclusion of other diseases [28] (Fig. 8).
Imaging studies indicate that neurodegenerative dis-
eases are caused by degeneration within specific intrin-
sic functional connectivity networks vulnerable to their 
pathologies [132, 165]. fMRI studies in bvFTD show 
attenuated connectivity within an anterior network of 
dorsal anterior cingulate and frontoinsular cortices con-
necting to subcortical and limbic structures [131, 166] and 
network disruption, with reduced mean network extent and 
increased path length, compared with healthy controls [1]. 
These results enable us to recognize sites of early disrup-
tion as vulnerable regions, and also throw light on the 
connectivity of the areas involved in the diseases. Further 
molecular pathological approaches will help to establish 
which aberrant proteins progress along networked brain 
structures, and whether specific pathological subtypes can 
be linked to specific forms of neural network degeneration 
[52].
Since the discovery of C9orf72 in 2011, the role of the 
repeat expansion in TDP-43 proteinopathy has been inves-
tigated by means of imaging techniques. Recent neuroimag-
ing analyses demonstrate that patients with C9orf72-positive 
bvFTD show symmetric atrophy most prominently in the 
anterior insula, anterior cingulate, and frontotemporal cor-
tex, in keeping with the sporadic bvFTD-associated pattern 
[23, 75, 104, 133, 155]. Some studies indicate that C9orf72 
carriers exhibit atrophy of the parietal lobe [75, 155] and 
occipital lobe [133, 155], which are not typically involved 
in bvFTD. A resting-state functional MRI study found that 
patients with bvFTD with or without C9orf72 expansion 
show convergent large-scale network breakdowns despite 
having distinctive atrophy patterns [96]. In ALS, extensive 
cortical and subcortical frontotemporal involvement has 
been reported in association with the C9orf72 genotype, 
compared to the relatively limited extramotor pathology 
in patients with C9orf72-negative ALS [19]. The changes 
in the orbitofrontal, fusiform, thalamic, superior temporal 
regions, and Broca area, and posterior cingulate in ALS are 
distinct from those seen in the C9orf72 genotype [19]. As for 
PET, C9orf72-positive ALS had a more widespread central 
nervous system involvement than C9orf72-negative ALS, 
with or without FTD comorbidity [38].
Strains and phenotypic diversity
Selective neuronal and regional susceptibility
Understanding the underlying causes is crucial for building 
effective treatment strategies. As described, neurodegenera-
tion in ALS selectively involves the upper and lower motor 
Fig. 8  Imaging of an FTLD-TDP patient showing the clinical presen-
tation of naPPA. Left photo shows T1-weighted MRI at onset (a) and 
2 years after onset (b). Frontal and temporal atrophy on axial slices 
(two photos on the left) is prominent. Coronal slices (two photos on 
the right) indicate atrophy in the dorsolateral prefrontal cortex and 
medial and inferior temporal cortex with enlargement of the temporal 
horn. Single-photon-emission computed tomography using techne-
tium-99 m ethyl cysteinate dimer (ECD-SPECT) revealed a reduction 
in the bifrontal regions (Right photo)
762 Acta Neuropathologica (2019) 138:751–770
1 3
neurons within the pyramidal motor system [134]. Motor 
neurons are different from many other neuronal cells in both 
size and shape. In addition, characteristic anatomical fea-
tures include a large cell body with a high level of mitochon-
drial activity and a long axonal process with a high content 
of neurofilament proteins [134]. Those anatomical features 
are associated with mRNA splicing, oxidative stress, pro-
teosomal and mitochondrial dysfunction, and glutamater-
gic toxicity with damage to critical target proteins in the 
pathogenesis of ALS [65, 134]. Also, axonal cytoskeletal 
disorganization has been considered as a conspicuous fea-
ture of ALS. ALS linked with mutations in TDP-43 shows 
impairment of the axonal transport of RNA granules in ani-
mal models of TDP-43 proteinopathy [3].
TDP-43 accumulations are detected in unaffected cells 
in ALS, though some Betz cells, which mainly degenerate 
in ALS, are known to lack TDP-43 accumulation [25, 59]. 
This may imply that there is no direct correlation between 
the presence of the accumulations and cell death. The Betz 
cells in upper motor neurons of patients display a distinct set 
of intracellular defects, especially at the nuclear membrane, 
mitochondria and endoplasmic reticulum [59]. Another 
argument against the hypothesis is that only cells with TDP-
43 accumulation cause degeneration. Previous data suggest 
that MND with ALS-linked mutants producing loss and gain 
of splicing function of selected RNA targets at an early dis-
ease stage does not require TDP-43 accumulation and loss 
of TDP-43 from the nuclei [10].
Many physiological and pathological studies indicate 
system degeneration in ALS and FTLD. ALS patients pre-
sent focal clinical symptoms showing upper or lower motor 
neuron predominance and clear alterations in motor func-
tion in one body region at a specific time, typically within a 
timescale of weeks to months [142]. The neuroanatomical 
distribution of pTDP-43 pathology allowed classification 
of FTLD cases into several clinical subtypes, as described 
above. Thus, the disease does not progress randomly across 
contiguous anatomical pathways [142]. It is important to 
consider the pattern of progression of neurodegeneration at 
the macroscopic level, in addition to the selective neuronal 
vulnerability at the microscopic level.
The vulnerable circuits and cell types in FTD have 
recently been investigated. Especially in bvFTD, von 
Economo neurons and fork cells within the anterior cingu-
late and ventral anterior insular cortices are affected in early 
degeneration [88, 111]. The large layer 5 projection neurons 
in the regions undergo early dropout in bvFTD [88, 111]. 
In addition, the presence of TDP-43 inclusions was associ-
ated with striking nuclear and somatodendritic atrophy and 
the inclusion fraction in those cells correlated with symp-
tom severity, such as loss of emotional empathy, in bFTD 
[111]. These insights regarding selective vulnerability and 
the mode of their progressive degeneration might lead to the 
identification of new targets for therapy and effective treat-
ments for numerous neurodegenerative diseases.
Current evidence regarding strains and progression
The different banding patterns of abnormal TDP-43 frag-
ments in ALS and FTLD may represent different TDP-43 
strains with different conformations. Biochemical analysis of 
different brain regions and spinal cord in individual patients 
with TDP-43 proteinopathy revealed three distinct C-termi-
nal banding patterns [40, 68, 147]. This strongly suggests 
that the same form of abnormal TDP-43 molecule is con-
sistently deposited in different brain regions in each patient. 
It is unlikely that the same conformational change would 
occur synchronously in different brain regions, and it seems 
more likely that abnormal protein produced in cells is trans-
ferred to different regions, transmitted from cell to cell and 
propagated in vivo [40, 68, 69, 72, 147]. In addition, novel 
cell-based techniques indicate that there are distinct forms 
of pathological TDP-43 with different biochemical features, 
which correlate with the FTLD subtypes; they manifest dis-
tinct neurotoxicities and show different seeding activities in 
culture [40, 68, 72].
In prion diseases such as CJD and bovine spongiform 
encephalopathy, the different patterns of protease-resistant 
bands can be used to identify the etiology of the diseases 
[40, 120]. For example, protease-resistant prion from new 
variant CJD exhibits a different banding pattern from that 
in sporadic CJD cases, and the band pattern was indistin-
guishable from that of mice infected with bovine spongiform 
encephalopathy prion. These observations are consistent 
with the idea that the different banding patterns of abnormal 
TDP-43 fragments in ALS and FTLD might represent differ-
ent TDP-43 strains with different conformations.
A hypothesis that has received much attention recently is 
that neurodegeneration might spread from cell to cell by a 
mechanism that is seen in prion diseases [117]. According 
to this hypothesis, abnormal insoluble TDP-43 in brains of 
patients exhibits prion-like properties. Recently, pathologi-
cal TDP-43 derived from FTLD-TDP brains was shown to 
induce formation of de novo TDP-43 pathology with subse-
quent spreading throughout the central nervous system in a 
region- and time-dependent manner in experimental animal 
models [122]. It was also reported that TDP-43 could be 
released from cells via secreted vesicles called exosomes. 
This could facilitate the propagation of prion-like TDP-43 
aggregates from one cell to others. The types of TDP-43 
aggregates (strains) initially generated in neuronal/glial cells 
spread to the neighboring cells and determine the TDP-43 
pathologies. One study found that inhibition of exosome 
secretion exacerbated the disease phenotypes of transgenic 
mice expressing human TDP-43 mutant [74]. Morphologi-
cal analyses of mouse primary cortical neurons, patients’ 
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fibroblasts, and stem cell-derived neurons showed that 
aggregation of TDP-43 triggered the sequestration and 
mislocalization of nucleoporins and transport factors, and 
interfered with nuclear protein import and RNA export [37].
Exogenous and environmental factors modulating 
selective regional vulnerability
Clinical studies suggest that traumatic brain injury (TBI) 
might be associated with an elevated risk of ALS, as well 
as other devastating neurodegenerative diseases [125, 126]. 
Chronic traumatic encephalopathy (CTE) is a neurodegen-
erative disease caused by repeated TBI associated with 
contact sports, and diseased brains contain abnormal accu-
mulations of hyperphosphorylated tau [106]. Head trauma 
induces focal axonal injury, microhemorrhage and gliosis in 
close proximity to the affected area, then p-tau accumulates 
in neurons in the perivascular regions due to axonal injury, 
breach of the blood–brain barrier, and neuroinflammation, 
and finally p-tau spreads throughout the brain [108]. A pre-
vious paper describes patients with repetitive head trauma 
who showed widespread TDP-43 inclusions in the CNS, 
including motor neurons [107]. A study in Drosophila mod-
els of ALS indicated that repetitive trauma promotes the 
accumulation of TDP-43, with SGs in the brain, and also 
exacerbates neurodegenerative phenotypes as indicated by 
mortality and locomotor dysfunction [4]. Reversible induc-
tion of TDP-43 in cortical neurons after traumatic injury was 
also observed in a mouse stab wound model of TBI [156]. A 
single instance of TBI might not necessarily cause TDP pro-
gression, but repetitive head trauma may initiate or modify 
the onset or progression of ALS [146]. The precise etiology 
remains unclear and further research is needed to elucidate 
the impact of trauma on TDP-43 propagation.
In terms of selective vulnerability, exposures outside the 
CNS may influence motor neurons themselves. Especially 
in the spinal cord, motor neurons lack the protection of the 
blood–brain barrier at the axon termini. The neuromuscular 
junction seems vulnerable and the retrograde transport of 
aberrant factors may be able to occur at this site in patients 
[142].
Experimental modeling of phenotypic diversity
The development of multiple experimental models of 
TDP-43 proteinopathy is essential to clarify the pathogenic 
mechanism underlying TDP-43 propagation. Protease-resist-
ant banding patterns of pathological insoluble TDP-43 are 
useful for biochemical classification of the subtypes [147]. 
Cell-to-cell transmission of TDP-43 aggregates also occurs 
in cell culture, and exosomes are likely to be involved in 
pathological TDP-43 propagation [51, 117, 135]. SH-SY5Y 
cells treated with insoluble TDP-43 extracted from ALS or 
FTLD-TDP brains expressed aggregates of phosphoryl-
ated and ubiquitinated TDP-43 in a self-templating manner 
[117]. Immunohistochemical analyses established that the 
C-terminal fragments of each disease type acted as seeds in 
these cells, inducing seed-dependent aggregation of TDP-43 
[117]. The seeding ability of insoluble TDP-43 was hardly 
affected by protease treatment, but was abrogated by for-
mic acid. Another study indicated that anterograde and ret-
rograde transport of TDP-43 oligomers occurs in cultured 
cells, providing support for the idea of cell-to-cell transmis-
sion of pathological TDP-43 [51]. Furthermore, residues 
274–353 are essential for the conversion of TDP-43 to amy-
loid-like fibrils, and aggregation of TDP-43 by seeding with 
different peptides induces various types of TDP-43 patholo-
gies [135]. These findings indicate that insoluble TDP-43 
has prion-like properties that likely play a role in disease 
progression of patients with TDP-43 proteinopathy.
As in the cases of tau and α-synuclein, the prion-like 
propagation of TDP-43 protein in vivo has been investi-
gated by injecting brain extracts from aged transgenic mice 
showing pathology, or synthetic protein fibrils, or extracts 
from brains of patients into mouse brains. Animal models 
of TDP-43 propagation are not easy to prepare, compared 
to models of tau and α-synuclein propagation. It is very 
difficult to prepare substantial amounts of natively folded 
recombinant proteins or fragments in E. coli, and so it is 
difficult to form synthetic amyloid-like TDP-43 fibrils [70]. 
In addition, unlike α-synuclein or tau, TDP-43 is localized in 
the nucleus and its expression is tightly self-regulated [14], 
which may stabilize the conformation of TDP-43 in vivo 
and prevent the formation of abnormal TDP-43 pathology 
in non-Tg mice. However, more recent studies succeeded in 
the formation of TDP-43 pathology with subsequent spread-
ing throughout the central nervous system in a region- and 
time-dependent manner by injecting pathological TDP-43 of 
FTLD-TDP into transgenic CamKIIa-hTDP-43NLSm mice, 
which overexpress mutant TDP-43 lacking a nuclear locali-
zation signal [122]. The propagation of TDP-43 pathology 
in the injected mice resulted in widespread cortical, hip-
pocampal, and subcortical pTDP-43 accumulation in both 
ipsilateral and contralateral hemispheres, consistent with 
cell-to-cell transmission of TDP-43 pathology following 
the neuroanatomical connectome from the injection site. 
Another report clarified phenotypic heterogeneity among 
mutant mice and identified distinct transcriptomic profiles 
corresponding to differing phenotypes. The authors observed 
changes linked with improved behavior in TDP-43 knock-in 
mouse with a human TARDBP gene, associated with down-
regulation of two known modifiers of neurodegeneration, 
Atxn2 and Arid4a, and upregulation of myelination and 
translation genes. Identifying the environmental factors that 
influence the delicate balance in the transcriptome of the 
brain might be a promising topic for future studies [154]. 
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Other physiological models indicate that aggregation and 
nuclear depletion are dispensable for neurodegeneration [55, 
154]. Further work is necessary to establish the relation-
ship between the seeding activity or strain-like properties of 
pathological TDP-43 in patients and the neuropathological 
phenotypes of the mice.
Concluding remarks
Increasing evidence indicates that ALS/FTLD-TDP disease 
progression is induced by cell-to-cell propagation of intra-
cellular aggregated proteins. Extensive biochemical and 
biophysical studies needed to clarify the pathomechanisms 
leading to the presence of distinct pathogenic TDP-43 strains 
in patients’ brains. Using genome editing technology, it 
should be possible to generate large knock-in animal models 
or human iPSCs to overcome overexpression, off-target, and 
mosaic effects, which could offer promising approaches for 
therapy [39]. In addition, cryo-electron microscopy (cryo-
EM) will be a promising method to clarify the strains of 
pathological TDP-43. As for tau, a recent report has revealed 
the structures of the disease-specific folds in the ordered 
cores of tau filaments, establishing the existence of molecu-
lar conformers [49].
Genome-wide association studies have uncovered over 
100 loci that are linked with ALS/FTLD [77]. Some ALS/
FTLD-TDP patients have a familial history of neurological 
and/or psychiatric diseases that might possibly be associ-
ated with unknown genetic mutations. [14] Identifying those 
mutations would be helpful to identify the factors modulat-
ing disease progression and to provide targets for develop-
ment of therapeutic interventions. Gene therapy or antisense 
oligonucleotide (ASO) therapy to knock out a relevant gene 
or to reduce expression of the protein might also be effective 
to prevent protein aggregation and prion-like propagation.
Recent years have seen a rapid development of fluid bio-
markers for FTLD. In C9orf72 mutation carriers, the con-
centration of poly GP, which is produced as an abnormal 
dipeptide repeat protein, could be a target biomarker, in 
addition to TDP-43 [164]. The development of an immuno-
assay method for its detection in CSF will be needed.
Identification of imaging biomarkers, such as amyloid-
imaging probes, that predict future clinical syndrome will 
be critical for the identification of suitable candidates for 
clinical trials. In addition, clinicopathological studies of 
TDP-43 are expected to provide deeper insights into dis-
ease mechanisms, although we should pay attention to the 
limitations involved in investigating patients with end-stage 
disease. Such studies should provide further support for the 
idea that clinical heterogeneity in patients is associated with 
the heterogeneity of TDP-43 neuropathology resulting from 
different TDP-43 strains.
Small molecular compounds that can pass through the 
blood–brain barrier, enter the cells, and bind to intracellular 
aggregates of abnormal proteins would be promising candi-
dates for pharmacotherapy of neurodegenerative diseases by 
promoting clearance of pathological TDP-43 proteins, e.g., 
by activating degradation or protein quality-control systems. 
Antibody therapy may also be feasible.
In conclusion, combinations of behavioral, functional, 
and physiological approaches to study the changes in the 
neuroanatomical system will be crucial for the development 
of future therapy. In addition, the clinically stereotyped 
nature of the disease progression, and neuronal brain imag-
ing studies, suggests that a system level vulnerability is a 
significant aspect of the biological underpinning of TDP-43 
proteinopathy.
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